At neuroCare, we offer sustainable outcomes in therapy for mental disorders, chronic pain and for rehabilitation. The individualised therapy concepts offered at neuroCare clinics are achieved by integrating the expertise of mental health therapists with leading neuromodulation technology. At neuroCademy we educate clinicians and researchers in the area of neuromodulation technologies and how to apply them in daily clinical practice. Development in research and patient care is anchored by the neuroConn technology brand, a global leader and industry pioneer in non-invasive neuromodulation technology.
Everything we do, think or feel is a memorized pattern in our brain or muscle memory. Neuromodulation helps to reprogram those patterns by training our mind to more positive behaviour or for better cognitive performance. Behavourial, cognitive or motor disturbances can be treated faster and more efficiently when neurotechnology and the therapist work in synergy. Our integrated approach (i.e. cognitive therapy combined with individualised neurotherapy) shows an efficacy of 75 % for patients with ADHD and an efficacy of 78 % for patients with depression. This is a fact we are truly proud of.
At neuroCare, we also apply neurotechnologies in the diagnosis of mental disorders allowing the therapist to personalize the treatment to the patient’s individual need - this is called prognostics. Most current treatments in mental health or neurology, particularly psychopharmaceuticals, still rely on a one-size-fits-all approach. Individual differences are ignored even though not all patients have the same underlying cause for their symptoms. Our integrated and personalized approach to therapy is needed. neuroCare is a leader in the fast growing neurotherapy market.
Everything we do, think or feel is a memorized pattern in our brain or muscle memory. Neuromodulation helps to reprogram those patterns by training our mind to more positive behaviour or for better cognitive performance. Behavourial, cognitive or motor disturbances can be treated faster and more efficiently when neurotechnology and the therapist work in synergy. Our integrated approach (i.e. cognitive therapy combined with individualised neurotherapy) shows an efficacy of 75 % for patients with ADHD and an efficacy of 78 % for patients with depression. This is a fact we are truly proud of.
At neuroCare, we also apply neurotechnologies in the diagnosis of mental disorders allowing the therapist to personalize the treatment to the patient’s individual need - this is called prognostics. Most current treatments in mental health or neurology, particularly psychopharmaceuticals, still rely on a one-size-fits-all approach. Individual differences are ignored even though not all patients have the same underlying cause for their symptoms. Our integrated and personalized approach to therapy is needed. neuroCare is a leader in the fast growing neurotherapy market.
Location: Germany, Bavaria, Munich
Total raised: $17.38M
Investors 4
Date | Name | Website |
- | bm-t betei... | bm-t.de |
- | Passion In... | passioninn... |
- | aescuvest | aescuvest.... |
- | re.Mind Ca... | remind.vc |
Funding Rounds 1
Date | Series | Amount | Investors |
04.06.2024 | - | $17.38M | TVM Capita... |
Mentions in press and media 13
Date | Title | Description |
25.07.2024 | Newsletter Q2/2024 | Here a Startup, There a Startup, Everywhere a Startup In April, we participated in a trip to Japan with a Thüringen delegation and were able to interact with the startup communities in Osaka and Tokyo, which were impressive. In ... |
04.06.2024 | TVM Capital Healthcare Announces EUR 16 Million Investment into neurocare | neurocare is revolutionizing mental health care by providing innovative methods and tools based on neurostimulation and other technologies to help clinicians deliver personalized treatments with sustainable clin... |
29.04.2024 | neurocare bekommt 16 Millionen – Deltia erhält 4,5 Millionen – roclub sammelt 4 Millionen ein | Im #DealMonitor für den 29. April werfen wir einen Blick auf die wichtigsten, spannendsten und interessantesten Investments und Exits des Tages in der DACH-Region. Alle Deals der Vortage gibt es im großen und übersichtlichen #DealMonitor-Ar... |
25.04.2024 | TVM Capital Healthcare led $ 17 M received by mental health care platform Neurocare | The Munich-based neurocare group AG (neurocare), a pioneer in individualized mental health care that offers tools to enable clinicians to provide the best care possible to their patients, has received a $17 million investment from TVM Capit... |
24.04.2024 | Breaking Boundaries: neurocare's Global Expansion | neurocare, a Munich-based mental health company, secures a hefty EUR 16M in funding from TVM Capital Healthcare. This investment fuels their mission to revolutionize personalized mental health care worldwide. Led by the visionary CEO Thomas... |
24.04.2024 | German mental health platform neurocare raises €16M | TVM Capital Healthcare has announced a €16M investment into Munich-based neurocare, a digital therapy platform for mental health treatment. Neurocare provides treatment for a variety of psychological or neurological conditions. Following a ... |
24.04.2024 | neurocare Raises EUR 16M in Funding | neurocare, a Munich, Germany-based personalized mental health care company, raised EUR 16M in funding. TVM Capital Healthcare made the investment. The company intends to use the funds to expand its international growth plans, including US a... |
- | neuroCare Group secures investment from bm|t to fund next growth stage | neuroCare´s mission is to empower clinicians with an evidence-based approach to integrate neuromodulation techniques into clinical practice. neuroCare personalises treatment following a detailed assessment and hence is... |
- | neurocare and MAG & More are joining forces | neurocare and MAG & More are very pleased to announce the integration of MAG & More into theneurocare group. MAG & More is a German based leader in the field of repetitive transcranialmagnetic stimulation (rTMS) ... |
- | neurocare announces financing round with bm|t and strategic investor Apeiron / re.Mind | As another key step towards its planned public listing, neurocare is very pleased to announce the closing of a significant financing round with its existing anchor investor bm|t and new strategic investor re.Mind, the mental hea... |
Show more